Special Issue "EGFR in Cancer: Innovative Insights into Signalling, Mutation and Therapeutic Targeting"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 December 2019
The epidermal growth factor receptor (EGFR) is one of the most frequently dysregulated tyrosine kinases in cancer. The cancers impacted include glioma, lung cancer, head and neck cancer and colon cancer, along with many others. EGFR dysregulation is driven by diverse mechanisms, including gene amplification, mutation, overexpression, improper interactions with other members of the ErbB family and inappropriate autocrine signaling. Interestingly, the primary mechanism of EGFR activation is comparatively tumor specific; kinase domain mutations are predominantly restricted to lung cancer for example.
The central role of EGFR dysregulation in cancer development has led to the development of both small molecule tyrosine kinase inhibitors and therapeutic antibodies. In some cancers (e.g., lung cancer) these have proven to be effective therapeutic strategies, but in other cancers (e.g., glioma) targeting EGFR has been ineffectual.
In this Special Issue, we will publish reviews and original research that provide new insights into the role of EGFR in cancer and how it can be targeted therapeutically. Novel insights into EGFR mutation and gene amplification will be particularly welcomed.
Prof. Terrance G. Johns
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- EGFR mutation
- EGFR signalling
- tyrosine kinase inhibitors
- antibody therapeutics
- EGFR gene amplification
- therapeutic resistance
- ErbB family